Neureliv – Epalrestat

Home / Neureliv – Epalrestat

Neureliv

50 mg Tablet Aldose reductase inhibitor
৳10.00
per unit
AI Summary Generated by AI for informational purposes only

এই ওষুধটি ডায়াবেটিসের কারণে হওয়া স্নায়ুর ক্ষতি বা নার্ভের সমস্যার চিকিৎসায় ব্যবহৃত হয়। এটি হাত ও পায়ে ব্যথা, ঝিনঝিন করা বা অবশ হয়ে যাওয়ার মতো উপসর্গ কমাতে সাহায্য করে। গর্ভাবস্থায় বা বুকের দুধ খাওয়ানোর সময় সাধারণত এটি ব্যবহার করার পরামর্শ দেওয়া হয় না।

Indications

Epalrestat is indicated for the improvement of subjective symptoms (numbness and pain), abnormality of vibration sense and abnormal change in heartbeat associated with diabetic peripheral neuropathy (when high glycohemoglobin value is noted).

Pharmacology

Epalrestat specifically inhibits aldose reductase and accumulation of sorbitol in the nerve; thereby improves subjective symptoms and nerve dysfunction in patients with diabetic peripheral neuropathy.

Dosage & Administration

Important:
Do not take any medication without a doctor's prescription. Self-medication can be dangerous.
The usual adult dose is 1 tablet (50 mg) three times daily before each meal. The dosage may be adjusted according to the patient's age and symptoms.

Interaction

There are no known drug interactions and none well documented.

Contraindications

The drug is contraindicated for patients with known hypersensitivity to epalrestat.

Side Effects

Major adverse reactions are hepatic function abnormalities and thrombocytopenia. In cases of hepatic abnormalities drug should be discontinued immediately and appropriate measures should be taken. Other reactions may be malaise, headache, abdominal pain, nausea, hypersensitivity reaction etc.

Pregnancy & Lactation

The safety of epalrestat in pregnant women has not been established. The drug may be used in pregnant women or in women who may possibly be pregnant only if expected therapeutic benefits outweigh the possible risks associated with the treatment. Breast-feeding should be avoided during administration of epalrestat.

Precautions & Warnings

The administration of Epalrestat should be considered to patients showing high glycohemoglobin values even after fundamental therapies for diabetes mellitus such as diet therapy, exercise therapy and treatment with an oral hypoglycemic agent, insulin etc. The efficacy of this product has not been established in patients with diabetic peripheral neuropathy with irreversible organic changes. The patient should be carefully monitored during the administration of this product. When the efficacy of this product is not observed even after 12 weeks of administration, other appropriate therapies should be taken.

Storage Conditions

Do not store above 30°C temperature. Keep away from light and wet place. Keep out of reach of children.

The information provided on this page is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. All brands listed might have copyright or trademark of their respective owners. Listed information may not be up-to-date or accurate. We do not guarantee the availability, quality, price or safety of any medication. Use at your own risk.

Similar Brands

2 found
Brand Strength
Aldorin 50 mg 11.00
Epastat 50 mg 10.00